Citadel Advisors
ROIV icon

Citadel Advisors’s Roivant Sciences ROIV Stock Holding History

Citadel Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197M Buy
5,576,261
+3,060,263
+122% +$90.4M 0.02% 561
2026
Q1 		$69.7M Buy
2,515,998
+229,997
+10% +$5.91M 0.01% 1089
2025
Q4 		$49.6M Buy
2,286,001
+1,317,798
+136% +$26M 0.01% 1421
2025
Q3 		$14.6M Buy
968,203
+476,071
+97% +$5.89M ﹤0.01% 2725
2025
Q2 		$5.55M Sell
492,132
-859,209
-64% -$9.31M ﹤0.01% 3923
2025
Q1 		$13.6M Sell
1,351,341
-453,438
-25% -$4.9M ﹤0.01% 2479
2024
Q4 		$21.4M Sell
1,804,779
-4,123,404
-70% -$48.8M ﹤0.01% 2095
2024
Q3 		$68.4M Buy
5,928,183
+4,004,146
+208% +$45.6M 0.01% 965
2024
Q2 		$20.3M Sell
1,924,037
-1,215,542
-39% -$13.3M ﹤0.01% 1984
2024
Q1 		$33.1M Sell
3,139,579
-342,124
-10% -$3.69M 0.01% 1566
2023
Q4 		$39.1M Buy
3,481,703
+3,355,500
+2,659% +$32.7M 0.01% 1370
2023
Q3 		$1.47M Buy
126,203
+101,024
+401% +$1.14M ﹤0.01% 5805
2023
Q2 		$254K Sell
25,179
-1,378,661
-98% -$12.3M ﹤0.01% 9378
2023
Q1 		$10.4M Buy
1,403,840
+539,869
+62% +$4.45M ﹤0.01% 2780
2022
Q4 		$6.9M Sell
863,971
-570,054
-40% -$3.17M ﹤0.01% 3349
2022
Q3 		$4.62M Buy
1,434,025
+1,246,676
+665% +$4.83M ﹤0.01% 4005
2022
Q2 		$762K Buy
+187,349
New +$744K ﹤0.01% 7653

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Citadel Advisors's ROIV Position: Q2 2026 in Review

Citadel Advisors increased its Roivant Sciences (ROIV) stake by 122% in Q2 2026, buying an estimated $90.4M and bringing the position to 5,576,261 shares worth $197M. The position accounts for 0.02% of the portfolio, ranked #561.

Citadel Advisors first reported a position in ROIV in Q2 2022 and has held it in 17 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Citadel Advisors held 5,576,261 shares of Roivant Sciences worth $197M as of Q2 2026.
  • Citadel Advisors bought 3,060,263 Roivant Sciences shares in Q2 2026, an estimated $90.4M.
  • Roivant Sciences made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #561 holding.
  • Citadel Advisors first reported a position in Roivant Sciences in Q2 2022 and has held it in 17 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.